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Objective The purpose of this study was to investigate and characterize in vitro the post-b-lactamase inhibitor
effect (PLIE) of clavulanic acid against two b-lactamase-producing species of bacteria.
Methods The PLIE was investigated against one strain of Klebsiella pneumoniae and one strain of Haemophilus
influenzae. A stationary-phase inoculum of about 107 colony-forming units per mL of each bacterium was
pre-exposed for 2 h to clavulanic acid, either alone or in combination with amoxicillin at various
concentrations. After pre-exposure, the dilution required to remove the b-lactamase inhibitor was 1:100 or
1:1000 according to the bacterial species and their susceptibilities to clavulanic acid. Bacteria were counted
hourly after drug removal, on solid agar medium.
Results Control cultures exposed to amoxicillin alone after dilution, showed a delay in growth, which may be
inherent to the time required to synthesize sufficient b-lactamase after the dilution steps. Control
experiments clearly distinguished the post-antibiotic effect and the growth delay from the PLIE.
Conclusion The PLIE could be one of several factors explaining why b-lactam/b-lactamase inhibitor
combinations remain effective throughout the dosing interval, even if a few hours after in vivo
administration, serum concentrations of b-lactamase inhibitor fall below levels that are active in vitro.
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INTRODUCTION
Studies of delays in bacterial growth after brief exposure to
antibiotics led to the concept of a ‘post-antibiotic effect’ (PAE)
[1]. The PAE has now been described both in vitro and in vivo.
The b-lactam agents, with the exception of carbapenems [2],
are characterized by short PAEs, especially against Staphylococcus
aureus and Escherichia coli.
Since 1981, the spread of bacterial resistance by b-lactamase
production has led to the use of b-lactamase inhibitors (bLI).
Their structures, which are close to those of b-lactam agents,
confer strong affinity for b-lactamases. Clavulanic acid (CA)
binds irreversibly to penicillinases, thereby protecting from
hydrolysis the antibiotic with which it is combined [3]. The
concentrations required in vitro for total inhibition of b-
lactamases from various bacterial species involved in human
infections have been reported elsewhere [4–7].
Unexpectedly, b-lactam/bLI combinations remain active in
vivo throughout the interval between two consecutive doses,
even though CA serum concentrations rapidly fall to values
below those active in vitro. This observation, made with orally
administered Augmentin [8], has also been described in an
infectious model in vitro [9]. The bactericidal activity of the
piperacillin–tazobactam combination is identical on Escherichia
coli and Pseudomonas aeruginosa whether it is administered every
6 h or every 8 h. In both cases, the tazobactam (bLI) concen-
tration falls below that necessary to lower the minimum inhi-
bitory concentration (MIC) in vitro after the 2nd or 3rd hour
following administration.
By analogy with the PAE, defined as residual antibacterial
activity, the above findings led us to study the delay in bacterial
regrowth linked to brief pre-exposure of cultures to CA alone
or to CA combined with amoxycillin (AMX). We first mea-
sured the PAE, which must be taken into account when
precisely assessing a post-b-lactamase-inhibitor effect (PLIE).
We also attempted to identify all delays in bacterial regrowth
due to the experimental conditions, the bacteria themselves, or
unknown mechanisms.
The aim of this study was to determine whether clavulanic
acid exhibits a PLIE against b-lactamase-producing Klebsiella
pneumoniae and Haemophilus influenzae.
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Amoxicillin sodium, titrated powder (lot 37152) and clavulanic
acid (lot BN 74) were provided by SmithKline Beecham (6220
Heppignies, Belgium). The stock antibiotic solutions and
working dilutions were made up in sterile distilled water.
Bacterial strains
Two clinical isolates were used. Klebsiella pneumoniae strain
T35025, was isolated by blood culture from a patient hospita-
lized in the cancer ward. Haemophilus influenzae strain G6333,
was isolated from the bronchoalveolar lavage fluid of a patient
from the surgical intensive care unit.
These bacteria have been proved to produce b-lactamases by
both nitrocefin test and difference in the MIC of AMX alone
and AMX/CA in combination. The MICs of both strains were
determined by the broth dilution reference method [10] and are
shown in Table 1.
Preparation of the inoculum
A bacterial culture incubated at 37 8C for 18 h was diluted in
Mu¨ller–Hinton broth to obtain an initial inoculum of approxi-
mately 107 colony-forming units (CFU)/mL.
Haemophilus influenzae was cultured in Mu¨ller–Hinton med-
ium supplemented with growth factors (hemin 15 mg/L;
NADP 15 mg/L; yeast extract 5 mg/L).
Methods
PAE and PLIE can only be determined after discarding the
drugs which were in contact with the bacteria during the pre-
exposure phase. In this study, we used the dilution method to
eliminate CA and/or AMX. The dilution factors were deter-
mined so that the resulting residual concentrations of bLI were
far below those required to inactivate the bacterial b-lactamases
in vitro, i.e. 0.12 mg/L for H. influenzae [4,5] and 2 mg/L for K.
pneumoniae [6].
Haemophilus influenzae was pre-exposed to 0.5, 1, or 2 mg/L
CA. It was therefore necessary to dilute the culture 1000-fold
(CA¼ 1 or 2 mg/L) or 100-fold (CA¼ 0.5 mg/L) to ensure
that residual CA concentrations were well below the minimum
active concentrations in vitro. In the case of K. pneumoniae, and
for the same reasons, the CA (2 or 4 mg/L) used in the pre-expo-
sure phase was eliminated by 1:100 dilution. CA and/or AMX
was eliminated by serial 10-fold dilution in sterile normal saline.
Figure 1 summarizes the manipulations used to reveal the
different phenomena.
Undiluted cultures not exposed to antibiotics were included
in each experiment as growth controls. Another culture was
submitted to the same dilution steps to check the viability of
residual bacteria after serial dilution.
Bacterial counts were performed every hour during the
initial phase (0–8 h) and then at 24 h. A sample of 100 mL
was taken from each culture and serially diluted 1:10 in sterile
normal serum. Each dilution (100mL) was seeded on ‘choco-
late’ agar medium (H. influenzae) or on agar medium with a
spiral system (K. pneumoniae). An Interscience Model DS device
was used to deposit 49.2 mL on the agar surface. The plates
were read after 24 h of incubation at 37 8C, either visually
(H. influenzae) or using a Scan 500 counter (Interscience, St
Nom-la-Brete`che) for K. pneumoniae.
Determination of the PLIE
The PLIE can be defined as the persistence of the inhibitory
effect of a bLI after contact with the bacterium and elimination
of the bLI. The PLIE can be assessed either after contact with
CA alone, or after contact with the combination AMX/CA.
The PLIE must be distinguished from a possible PAE and delay
in growth (DG) due to the experimental conditions. The
bacteria were thus pre-exposed either to CA alone for 2 h at
concentrations of 2 and 4 mg/L (K. pneumoniae) or 0.5 and
1 mg/L (H. influenzae), or to AMX/CA combinations at con-
centrations of 8/2 and 16/2 mg/L (K. pneumoniae) and 1/0.5, 4/
2 and 8/2 mg/L (H. influenzae).
Table1 Susceptibilities of strains to amoxicillin (AMX), clavulanic acid (CA)
and amoxicillinþclavulanic acid (2mg/L)
MIC (mg/L)
Strains AMX CA AMXþCA
K. pneumoniae >256 64 4
H. influenzae 32 >32 1
Figure1 General technical procedures investigating each of the effects stu-
died: AMC, amoxicillinþclavulanic acid (2mg/L); CA, clavulanic acid; AMX,
amoxicillin; PAE, post-antibiotic effect; PLIE, post-b-lactamase-inhibitor ef-
fect; DG, delay in growth.
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To detect a possible PAE of AMX/CA, cultures were pre-
exposed for 2 h to AMX/CA concentrations of two-fold and
four-fold MIC (K. pneumoniae), and four-fold MIC and eight-
fold MIC (H. influenzae) (MICs measured in the presence of
2 mg/L CA). A delay in growth due solely to the experimental
conditions was tested for by using a bacterial culture incubated
at 37 8C for 2 h in drug-free medium then diluted (1:100 for K.
pneumoniae and 1:1000 for H. influenzae) in Mu¨ller–Hinton
broth and placed in contact with AMX for 24 h at 37 8C (8 and
16 mg/L for K. pneumoniae; 4, 8 and 16 mg/L for H. influenzae).
Serial dilution and bacterial counting at the highest dilutions
allowed us to limit antibiotic carry-over to the counting
medium. The counts are expressed in graphical form (log
CFU/mL vs. time). The experimental conditions used to
investigate each effect with the two strains are summarized
in Table 2.
Calculation of PAE
PAE was calculated as PAE¼TC, where T is the time
necessary for viable bacteria in the test culture to grow by
one log10 and C is the time necessary for viable bacteria in the
control culture to grow by one log10, relative to the number of
bacteria present just after the dilution step.
Calculation of PLIE
Following pre-exposure to CA alone any delay in growth
was subtracted from the total delay in renewed growth observed
relative to the control culture, i.e. PLIE¼ total delayDG.
Following pre-exposure to AMXþCA both the DG,
related to the experimental conditions, and the PAE, related
to the pre-exposure to AMXþCA combination, were sub-
tracted from the total delay in renewed growth, i.e.
PLIE¼ total delay (DGþPAE).
RESULTS
Klebsiella pneumoniae
No PAE was found at AMX/CA concentrations of two- or
four-fold the MIC. A brief DG (0.5–1.5 h) was observed at
AMX concentrations of 8 and 16 mg/L, respectively.
The PLIE, calculated by taking into account the DG
associated with the relevant AMX concentration, had the
following values: 0.5–1 h after pre-exposure to AMX/CA 8/
2 mg/L (n¼ 2) and 2.5–5 h after exposure to 16/2 mg/L
(n¼ 3).
After pre-exposure to CA, with an added AMX concentra-
tion of 8 mg/L, and regardless of the CA concentration to
which cultures were pre-exposed (2 and 4 mg/L), no significant
PLIE was observed (0 h, n¼ 3; 0.5 h, n¼ 1).
In contrast, at an AMX concentration of 16 mg/L, taking
into account the corresponding DG, the PLIE lasted, respec-
tively, 0 h and 0.5–4.5 h at CA concentrations of 2 and 4 mg/L
(Table 3).
Haemophilus influenzae
The delay in growth linked to the dilution and to contact
between the diluted culture and AMX correlated directly
with the AMX concentration added. The DG was short at
AMX¼ 4 mg/L (0 h and 1 h; n¼ 2), rising to 5, 7 and 7.5 h at
AMX¼ 8 mg/L and to 9 or 13 h at AMX¼ 16 mg/L; the latter
was accompanied by bactericidal activity of 1–2.5 log.
AMX/CA only had a PAE at concentrations at least four-fold
the MIC (1–2 h). No delay in growth was observed at an AMX/
CA concentration of 1/0.5 mg/L. After pre-exposure of the
culture to four- or eight-fold the MIC, a relatively short PAE
(between 0 and 2 h) was observed (0 h, n¼ 2; 1 h, n¼ 1; 2 h,
n¼ 1).
Table 2 Summary of experimental conditions used to investigate each effect
K. pneumoniae H. influenzae
DG PAE PLIE DG PAE PLIE
AMX/CA concentrations before dilution (mg/L) ^ 8/2 8/2 ^ 1/0.5 1/0.5
^ 16/2 16/2 ^ 4/2 4/2
^ ^ ^ ^ 16/2 8/2
CA concentrations before dilution ^ ^ 2 ^ ^ 0.5
^ ^ 4 ^ ^ 1




AMX concentrations added after dilution (mg/L) 8 ^ 8 4 ^ 1
16 ^ 16 8 ^ 4
^ ^ ^ 16 ^ 8
aOnly when CA¼0.5mg/L.
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The PLIE after contact with AMX/CA was calculated by
subtracting the respective DG and PAE values. No PLIE was
observed after exposure to AMX/AC at 1/0.5. In contrast, a
very long PLIE was observed after pre-exposure to AMX/CA
at four-fold the MIC (12–14.5 h) and at eight-fold the MIC
(6–12 h) with this strain of H. influenzae (Table 3).
The PLIE after pre-exposure to CA (0.5 mg/L) ranged from
0 to more than 7 h, apparently in proportional with the AMX
concentrations added after the dilution step. When the AMX
concentration was 1 mg/L, no PLIE was observed. The PLIE
lasted, respectively, 2 h (n¼ 2), 5 h to more than 7 and 1–3 h
with AMX concentrations of 4, 8 and 16 mg/L.
The PLIE was longer when the cultures were pre-expo-
sed to 1 mg/L CA: it lasted from 4 to 6.5 h when the
AMX concentration was 4 mg/L, more than 3 h and 4 h at
AMX¼ 8 mg/L and more than 3 h and 8 h at AMX¼ 16 mg/L
(Figure 2).
With H. influenzae, pre-exposure to CA 0.5 or 1 mg/L was
always associated with a PLIE, the duration of which increased
with the AMX concentration (except with CA¼ 0.5 mg/L and
AMX¼ 1 mg/L). On the other hand, the PLIE against K.
pneumoniae after pre-exposure to CA alone necessitated a high
concentration of both CA and added AMX (CA¼ 4 mg/L;
AMX¼ 16 mg/L; PLIE¼ 0.5 and 4.5 h).
DISCUSSION
The PLIE identified here clearly contributed to the delay in
growth observed with the species tested. It can only be observed
in the presence of a penicillin-binding protein inhibitor (in this
case amoxicillin) added after the withdrawal of the bLI. The
PLIE was clearly distinct from the PAE (the antibiotic in this
case being AMXþCA) and from any delay in growth due to
simple bacterial dilution in the absence of antibiotics.
Overall, the PLIE observed with H. influenzae was longer
than that observed with K. pneumoniae. This finding, which is in
keeping with data from Thorburn et al. [11], is probably due to
the higher in vitro inhibitory activity of CA on b-lactamases
from H. influenzae than on those from the Enterobacteriaceae.
Contrary to Thorburn et al. [11], we found that pre-exposure
to CA alone yielded a PLIE against both species. It was shorter-
lived than that observed after pre-exposure to AMX/CA, and
seemed proportional to the concentration of CA used during
the pre-exposure step. Other authors [12] have shown that the
bactericidal activity obtained with the ticarcillin–CA combina-
tion on b-lactamase-producing Klebsiella aerogenes or E. coli is
dependent on the concentration of the bLI and the contact time.
In the case of K. pneumoniae, pre-exposure to CA 2 mg/L
alone was not associated with a PLIE. In contrast, combina-
tion of CA 2 mg/L with AMX (8 or 16 mg/L) during the
Table 3 PLIE values observed afterAMXþCA or CA alone pre-exposures
Strain AMX/CAa CA/AMXb PLIE (h)














aAMX/CA, concentrations of AMX and CA used in pre-exposure (mg/L).
bCA/AMX, concentrations of CA used in pre-exposure and of AMX added
after dilution (mg/L).
Figure 2 Evidence for PLIE after CA or AMX/
CA exposure againstH. influenzae: CA1, clavula-
nic acid1mg/L;AMX8, amoxicillin 8mg/L; AMC
8/2, amoxicillin 8mg/Lþ clavulanic acid 2mg/L;
PLIE, post-b-lactamase-inhibitor effect.
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pre-exposure step led to a PLIE lasting 0.5–4.5 h. This tends to
confirm the partial bLI role played by AMX itself during the
contact phase, and explains the PLIE linked to pre-exposure to
the combination. In fact, AMX seems to compensate for the
absence of CA. When CA is added alone, at a high enough
concentration, during the pre-exposure phase (4 mg/L), a PLIE
is observed (Table 3) if the AMX concentrations added after
dilution are high enough (16 mg/L). An alternative explanation
for the enhanced effect seen in the presence of AMX could be
that the antibacterial activity of AMX allows better penetration
of the CA into the periplasmic space, where the b-lactamase of
these Gram-negative bacteria primarily resides.
In the clinical setting, b-lactamase-producing pathogens
treated with oral or parenteral AMX/CA are initially exposed
to high concentrations of the two compounds, but the CA
concentration rapidly becomes theoretically ineffective because
of the lower unit dose relative to AMX.
From the 6th hour onwards, CA concentrations are theore-
tically subinhibitory for many b-lactamases [13–15]. AMX is
therefore the only component effectively present beyond the
6th hour after dosing. Nevertheless, several recent clinical
studies have shown identical efficacy of b-lactam/bLI combi-
nations administered twice a day or three times a day [13,16] in
acute otitis media in children and in lower respiratory tract
infections in adults. The PLIE is undoubtedly one of the factors
contributing to those phenomena.
The mechanism of the PLIE observed in vitro remains
hypothetical. After b-lactamase inhibition by AMX/CA or
CA during the pre-exposure phase, followed by the elimination
of CA, the surviving bacteria might require a ‘latency period’ to
synthesize a sufficient level of b-lactamases. During this period
the amoxicillin still present can fully exert its antibiotic activity
(and perhaps a partial inhibitory role too) and inhibits bacterial
growth until the b-lactamase concentration is again sufficient to
hydrolyze AMX and allows bacterial regrowth.
A study conducted in vitro [17] with concentrations mimick-
ing serum levels of CA after administration of 125 mg has shown
that the b-lactamase activity of Staphylococcus aureus remains very
low even though CA concentrations are close to zero after the
8th hour.
In conclusion, the PLIE may be one of the mechanisms under-
pinning the efficacy of b-lactam/bLI combinations beyond the
6th hour after administration. Other studies are required to
confirm that this phenomenon occurs with other bacterial
species producing b-lactamases, especially E. coli and S. aureus.
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